{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=rituximab&page=23", "query": { "intervention": "rituximab", "page": 23 }, "page_size": 10 }, "pagination": { "page": 23, "page_size": 10, "total_count": 1303, "total_pages": 131, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=rituximab&page=24&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=rituximab&page=22&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-26T03:41:49.877Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02391545", "title": "A Study of Duvelisib in Combination With Rituximab or Obinutuzumab in Subjects With Previously Untreated CD20+ Follicular Lymphoma (CONTEMPO)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "CD20+ Follicular Lymphoma" ], "interventions": [ { "name": "Duvelisib", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Obinutuzumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SecuraBio", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 55, "start_date": "2014-12", "completion_date": "2017-05", "has_results": true, "last_update_posted_date": "2023-09-28", "last_synced_at": "2026-10-26T03:41:49.877Z", "location_count": 5, "location_summary": "Los Angeles, California • Palo Alto, California • Hackensack, New Jersey + 2 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "Rochester", "state": "New York" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02391545" }, { "nct_id": "NCT01399372", "title": "Rituximab, Methotrexate, Vincristine Sulfate, Procarbazine Hydrochloride, and Cytarabine With or Without Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chemotherapeutic Agent Toxicity", "Cognitive/Functional Effects", "Lymphoma", "Neurotoxicity", "Radiation Toxicity" ], "interventions": [ { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Procarbazine", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "low-dose whole-brain radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "RADIATION" ], "sponsor": "Radiation Therapy Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 91, "start_date": "2011-09", "completion_date": "2022-05-20", "has_results": true, "last_update_posted_date": "2023-07-20", "last_synced_at": "2026-10-26T03:41:49.877Z", "location_count": 44, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 34 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01399372" }, { "nct_id": "NCT00498316", "title": "Cord Blood Expansion on Mesenchymal Stem Cells", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Myelodysplastic Syndrome", "Leukemia" ], "interventions": [ { "name": "Cord Blood Infusion", "type": "PROCEDURE" }, { "name": "Busulfan", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "ATG", "type": "OTHER" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Clofarabine", "type": "DRUG" }, { "name": "Total Body Irradiation (TBI)", "type": "RADIATION" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Mycophenolate Mofetil", "type": "DRUG" }, { "name": "G-CSF", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG", "OTHER", "RADIATION" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "80 Years", "sex": "ALL", "summary": "1 Year to 80 Years" }, "enrollment_count": 98, "start_date": "2007-07-03", "completion_date": "2016-10", "has_results": false, "last_update_posted_date": "2020-02-28", "last_synced_at": "2026-10-26T03:41:49.877Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00498316" }, { "nct_id": "NCT00069758", "title": "Safety and Activity of SDX-105 (Bendamustine) in Patients With Rituximab Refractory Non-Hodgkin's Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Hodgkin's Lymphoma" ], "interventions": [ { "name": "SDX-105", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cephalon", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 72, "start_date": "2003-09", "completion_date": "2007-04", "has_results": false, "last_update_posted_date": "2014-05-09", "last_synced_at": "2026-10-26T03:41:49.877Z", "location_count": 13, "location_summary": "Birmingham, Alabama • Palm Springs, California • Vista, California + 10 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Palm Springs", "state": "California" }, { "city": "Vista", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Boise", "state": "Idaho" } ], "official_url": "https://clinicaltrials.gov/study/NCT00069758" }, { "nct_id": "NCT01184885", "title": "A Pilot Study to Determine the Safety and Tolerability of Sirolimus Given With Hyper-CVAD Chemotherapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Lymphoid Malignancies (New or Relapsed)", "Acute Lymphoblastic Leukemia", "Burkitt Lymphoma", "Lymphoblastic Lymphoma", "Mantle Cell Lymphoma", "Adult T-cell Leukemia/Lymphoma" ], "interventions": [ { "name": "Hyper-CVAD", "type": "DRUG" }, { "name": "Sirolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 7, "start_date": "2010-07", "completion_date": "2013-04", "has_results": true, "last_update_posted_date": "2025-05-04", "last_synced_at": "2026-10-26T03:41:49.877Z", "location_count": 2, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01184885" }, { "nct_id": "NCT02747043", "title": "Study to Assess if ABP798 is Safe & Effective in Treating Non Hodgkin Lymphoma Compared to Rituximab", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Lymphoma, Non-Hodgkin" ], "interventions": [ { "name": "ABP 798", "type": "BIOLOGICAL" }, { "name": "Rituximab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 256, "start_date": "2016-05-25", "completion_date": "2019-06-28", "has_results": true, "last_update_posted_date": "2022-09-10", "last_synced_at": "2026-10-26T03:41:49.877Z", "location_count": 5, "location_summary": "Encinitas, California • Mount Sterling, Kentucky • Billings, Montana + 2 more", "locations": [ { "city": "Encinitas", "state": "California" }, { "city": "Mount Sterling", "state": "Kentucky" }, { "city": "Billings", "state": "Montana" }, { "city": "Zanesville", "state": "Ohio" }, { "city": "Roanoke", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02747043" }, { "nct_id": "NCT01554514", "title": "Low Dose Rituximab in Thrombotic Thrombocytopenic Purpura", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Thrombotic Thrombocytopenic Purpura" ], "interventions": [ { "name": "rituximab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 19, "start_date": "2012-08", "completion_date": "2020-02-14", "has_results": true, "last_update_posted_date": "2021-08-17", "last_synced_at": "2026-10-26T03:41:49.877Z", "location_count": 4, "location_summary": "Atlanta, Georgia • Boston, Massachusetts • St Louis, Missouri + 1 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01554514" }, { "nct_id": "NCT03391466", "title": "Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)" ], "interventions": [ { "name": "Axicabtagene Ciloleucel", "type": "BIOLOGICAL" }, { "name": "Platinum-containing Salvage Chemotherapy", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Kite, A Gilead Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 359, "start_date": "2018-01-25", "completion_date": "2024-11-25", "has_results": true, "last_update_posted_date": "2025-12-01", "last_synced_at": "2026-10-26T03:41:49.877Z", "location_count": 30, "location_summary": "Gilbert, Arizona • Phoenix, Arizona • La Jolla, California + 24 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03391466" }, { "nct_id": "NCT01206777", "title": "Feasibility Study of a 60 Minute Rapid Infusion Rituximab Protocol in Patients With B-cell Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Indolent or Intermediate Grade B-cell Malignancy" ], "interventions": [ { "name": "Rituximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ohio State University Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "89 Years", "sex": "ALL", "summary": "18 Years to 89 Years" }, "enrollment_count": 52, "start_date": "2010-10", "completion_date": "2013-04", "has_results": true, "last_update_posted_date": "2017-12-20", "last_synced_at": "2026-10-26T03:41:49.877Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01206777" }, { "nct_id": "NCT04935177", "title": "Renal Function in Highly Sensitized Patients 1 Year After Desensitization With Imlifidase Prior to DD Kidney Tx", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Kidney Transplantation in Highly Sensitized Patients" ], "interventions": [ { "name": "Imlifidase", "type": "DRUG" }, { "name": "PLEX", "type": "PROCEDURE" }, { "name": "IVIg", "type": "DRUG" }, { "name": "Anti-CD20 antibodies", "type": "DRUG" }, { "name": "Eculizumab", "type": "DRUG" }, { "name": "Remain on wait list", "type": "OTHER" } ], "intervention_types": [ "DRUG", "PROCEDURE", "OTHER" ], "sponsor": "Hansa Biopharma AB", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 64, "start_date": "2021-10-14", "completion_date": "2025-06-20", "has_results": false, "last_update_posted_date": "2026-04-30", "last_synced_at": "2026-10-26T03:41:49.877Z", "location_count": 25, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 16 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04935177" } ] }